Safety
diarrhoea, death, fatigue, toxicity, pruritus
ADVERSE EVENTS, DISEASE
Overall, only 16 (13%) patients completed the treatment as initially scheduled and treatment was discontinued prematurely in most patients (87%) mainly due to: the progression of the disease 74 (60.2%), unacceptable toxicity 12 (9.8%), death 6 (4.9%) or physician criteria 4 (3.3%) (Fig. Most treatment-related adverse events (TRAEs) were mild and resolved with appropriate clinical care; the most common TRAEs across the cohorts were: fatigue (44.7%), diarrhoea (32.5%) and pruritus (23.6%) (Supplementary Table 